OSSIO

Executive Summary

OSSIO is a pre-clinical medical device company pioneering intelligent bone regeneration technology through its flagship OSSIOfiber® implant material. OSSIOfiber is a bio-integrative composite designed to securely fixate bone fractures and then fully remodel into native bone, eliminating the need for permanent metal hardware. This approach aims to address significant clinical challenges associated with metal implants, including stress shielding, chronic inflammation, and the requirement for secondary removal surgeries, which affect millions of orthopedic patients annually. The company's innovation targets a large market opportunity in orthopedic fixation, potentially reducing complications and healthcare costs while improving patient outcomes. Currently at the pre-clinical stage, OSSIO is focused on advancing OSSIOfiber through the regulatory pathway, with key milestones including animal studies, IDE submission, and eventual human clinical trials. Given the early stage, the company faces typical risks of medical device development, including regulatory hurdles, clinical validation, and capital needs. However, its technology addresses a clear unmet need and has the potential to disrupt the orthopedic implant market. Success will depend on achieving regulatory approvals and gaining surgeon adoption, but the foundational science and market interest appear promising.

Upcoming Catalysts (preview)

• Q2 2027Completion of pivotal preclinical study and submission of Investigational Device Exemption (IDE) to FDA70% success
• Q4 2026Announcement of strategic partnership or licensing deal for OSSIOfiber technology40% success
• Q1 2028Initiation of first-in-human clinical trial for OSSIOfiber50% success